Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder

Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal, have developed and successfully tested in human neurons cultured in the lab a new approach for treating the rare neurodegenerative disease spinocerebellar ataxia type 3 (SCA3).

Read it at Medical Xpress ↗

← Front page